2021 Volume 38 Issue 3 Pages 391-394
In this case series, we described two patients of spinocerebellar ataxia type 3 (SCA 3) administered intrathecal baclofen (ITB). Patient 1 was 46–year–old man presented lower limbs with pain during walking. ITB improved spasticity and pain, which led to an extension of walking distance. Patient 2 was 36–year–old woman presented severe spasticity in upper and lower limbs, which made it difficult to care for her. ITB improved spasticity and care burden. We observed no adverse events in both patients. ITB is an effective therapeutic option for spasticity and might be useful for pain and caregiving.
